ArticleWorld journal of gastroenterology2014
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.
Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- A Systematic Review of Clinical Validated and Potential miRNA Markers Related to the Efficacy of Fluoropyrimidine Drugs.Disease markers · 2022Pooled it
- Cell-Free DNA Release Kinetics and Fragmentation Reflect Treatment Response and Resistance In Vitro.Cells · 2026Article
- Analysis of the Circulating miRNome Expression Profile in Saliva Samples After Neoadjuvant Chemoradiotherapy in a Rectal Cancer Study Population Using Next-Generation Sequencing.International journal of molecular sciences · 2025Article
- Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma.International journal of molecular medicine · 2024Article
- Cranberry Proanthocyanidins Mitigate Reflux-Induced Transporter Dysregulation in an Esophageal Adenocarcinoma Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Identification of hub genes and microRNAs with prognostic values in esophageal cancer by integrated analysis.Non-coding RNA research · 2023Article
- Analysis and Validation of the Prognosis ability of the M7GRelated miRNAs in Lung Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours.International journal of molecular sciences · 2023Article
- Circulation microRNA expression profiles in patients with complete responses to chemoradiotherapy in nasopharyngeal carcinoma.Non-coding RNA research · 2022Article
- Article
- The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer.Cancers · 2022Review
- Molecular mechanisms associated with chemoresistance in esophageal cancer.Cellular and molecular life sciences : CMLS · 2022Review
- CircLONP2 Accelerates Esophageal Squamous Cell Carcinoma ProgressionFrontiers in oncology · 2022Article
- Analysis of cancer-promoting genes related to chemotherapy resistance in esophageal squamous cell carcinoma.Annals of translational medicine · 2022Article
- The role of non-coding RNAs in chemotherapy for gastrointestinal cancers.Molecular therapy. Nucleic acids · 2021Review
- Emerging Role of MiR-192-5p in Human Diseases.Frontiers in pharmacology · 2021Review
- Novel Implications of MicroRNAs, Long Non-coding RNAs and Circular RNAs in Drug Resistance of Esophageal Cancer.Frontiers in cell and developmental biology · 2021Review
- Network analysis of miRNA targeting m6A-related genes in patients with esophageal cancer.PeerJ · 2021Article
- Expression of miRNA in 5-FU resistant esophageal cancer.Molecular and clinical oncology · 2020Article
- miRNA-181a-5p Enhances the Sensitivity of Cells to Cisplatin in Esophageal Adenocarcinoma by Targeting CBLB.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate expression of microRNA (miRNA) and potential targets in chemotherapy resistant esophageal cancer cell lines.
methodsAn in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated.
resultsChemotherapy resistant sublines were found to have specific miRNA signatures, and these miRNA signatures were different for the cisplatin vs 5-FU resistant cells from the same tumor cell line, and also for EAC vs ESCC cells with resistance to the same specific chemotherapy agent. Amongst others, miR-27b-3p, miR-193b-3p, miR-192-5p, miR-378 a-3p, miR-125a-5p and miR-18a-3p were dysregulated, consistent with negative posttranscriptional control of KRAS, TYMS, ABCC3, CBL-B and ERBB2 expression via these miRNAs.
conclusionThe current study supports the hypothesis that microRNA expression has an impact on chemotherapy resistance in esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.